Back Hepatitis C

Hepatitis C

PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C

A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.

alt

EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.

alt

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, in Seattle.

alt

Antiretroviral Therapy and Treatment Strategies

HIV Cure Research

HIV Prevention

HIV-Related Conditions and Complications

HIV Epidemiology and Access to Care

Hepatitis C and HIV/HCV Coinfection

Tuberculosis

 

EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates

Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.

alt

Coverage of the 2017 EASL International Liver Conference

HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver (EASL), April 19-23, 2017, in Amsterdam

Full coverage listing by topic

International Liver Congress website

4/30/17

alt

EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List

Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.

alt

EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis

A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.

alt

Coverage of the 2017 EASL International Liver Congress

HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver, April 19-23, 2017, in Amsterdam.

alt

EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir

Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.

alt